Filing Details

Accession Number:
0001209191-18-007710
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-02-05 20:04:45
Reporting Period:
2018-02-01
Accepted Time:
2018-02-05 20:04:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1001233 Sangamo Therapeutics Inc SGMO Biological Products, (No Disgnostic Substances) (2836) 680359556
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1691262 Iii A. Curt Herberts C/O Sangamo Therapeutics, Inc.
Point Richmond Tech Ctr, 501 Canal Blvd.
Richmond CA 94804
Sr.vp & Chief Business Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-02-01 15,000 $3.50 29,625 No 4 M Direct
Common Stock Disposition 2018-02-01 15,000 $20.59 14,625 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2018-02-01 15,000 $0.00 15,000 $3.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
60,000 2027-01-25 No 4 M Direct
Footnotes
  1. All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017.
  2. The price reported is a weighted average price. The shares were sold at prices ranging from $20.25 to $20.95 The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. Includes (a) 8,375 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date; and (b) 6,250 shares subject to restricted stock units granted on December 8, 2015 that will vest on December 8, 2018, subject to the Reporting Person's continued service with the Issuer through such date.
  4. The stock option vested and became exercisable for 25% of the shares upon the Reporting Person's completion of one year of service measured from the January 26, 2017 grant date, and the balance of the shares will vest and become exercisable in 36 successive equal monthly installments upon his completion of each additional month of service thereafter.